Drug intelligence / Profile preview

gsk729327

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK729327 is a selective positive allosteric modulator of AMPA-type ionotropic glutamate receptors. It exhibits equivalent potency at all AMPA receptor subtypes and was developed with the aim of improving cognitive measures in patients with schizophrenia. The drug was initially developed by GSK Plc and has been evaluated in clinical trials for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers[1][2][3]. Preclinical studies suggested potential benefits for cognitive deficits associated with schizophrenia.

Other names: execliminreldebrel

Targets

AMPAR (AMPA receptor)

Beyond the preview

Go deeper on gsk729327.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gsk729327.

Explore the full profile